scholarly journals Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece

2005 ◽  
Vol 11 (10) ◽  
pp. 820-824 ◽  
Author(s):  
J. Papaparaskevas ◽  
A. Pantazatou ◽  
A. Katsandri ◽  
N.J. Legakis ◽  
A. Avlamis
1997 ◽  
Vol 41 (5) ◽  
pp. 1190-1192 ◽  
Author(s):  
J L Watts ◽  
S A Salmon ◽  
M S Sanchez ◽  
R J Yancey

The in vitro activity of premafloxacin against 673 veterinary pathogens was evaluated. Premafloxacin was equivalent to ciprofloxacin, enrofloxacin, and danofloxacin in activity against the gram-negative bacilli but was much more active (MIC for 90% of the strains tested [MIC90], 0.015 to 0.25 microg/ml) than the comparison antimicrobial agents (MIC90, 0.13 to 16.0 microg/ml) against the staphylococci, streptococci, and anaerobes tested.


1994 ◽  
Vol 38 (10) ◽  
pp. 2362-2368 ◽  
Author(s):  
E Di Modugno ◽  
I Erbetti ◽  
L Ferrari ◽  
G Galassi ◽  
S M Hammond ◽  
...  

2001 ◽  
Vol 45 (6) ◽  
pp. 1896-1899 ◽  
Author(s):  
Niels Kleinkauf ◽  
Grit Ackermann ◽  
Reiner Schaumann ◽  
Arne C. Rodloff

ABSTRACT The in vitro activity of gemifloxacin was compared to that of other quinolone and nonquinolone antimicrobials against 204 anaerobes by the agar dilution technique. The data indicate that gemifloxacin has a rather selective anaerobic activity. Most Peptostreptococcus, Porphyromonas, and Fusobacterium species are susceptible, while gemifloxacin's activity against other gram-negative anaerobes appears to be variable.


1999 ◽  
Vol 43 (12) ◽  
pp. 2996-2997 ◽  
Author(s):  
Peter C. Fuchs ◽  
Arthur L. Barry ◽  
Steven D. Brown

ABSTRACT SCH27899, an everninomicin antibiotic, was tested for its in vitro activity against 718 bacterial isolates representing 27 species. TheEnterobacteriaceae and nonenteric gram-negative bacilli were resistant to ≥8.0 μg/ml, but all others were inhibited by ≤1.0 μg/ml. When tested in combination with 17 other antimicrobial agents against 110 strains, SCH27899 demonstrated no significant antagonism or synergy. Consequently, combination therapy is not contraindicated.


Sign in / Sign up

Export Citation Format

Share Document